Citius Oncology, Inc. (CTOR)
Citius Oncology, Inc. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Cranford, NY, US. The stock last traded at $0.79, up 8.89% on the session, giving a market capitalisation of $73.9M. On trailing twelve-month figures it carries a trailing P/E of -1.69, a net margin of -757.6%. Its beta of 3.49 implies it has historically moved more than the broad market.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Citius Oncology, Inc. is most often compared with the following Healthcare names: